Prothena
NASDAQ: PRTADun Laoghaire, Co. Dublin, US · Founded 2012 · Ireland corporation · 85 employees on LinkedIn · 4 known investors
Find your way into Prothena
184 people in our graph share verified history with the Prothena team — schools, employers, funds. One of them is your warm intro.
Camila Vieiraunlockedknows Carol D. Karp · together at University of Rochester (overlapped)
×10knows the team · via University of Rochester
knows the team · via Amyris
Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.
Founders & leadership
TB
Tran B. NguyenExecutive
AW
Arthur W. HomanExecutive
KL
Karin L. WalkerinSVP, Chief Accounting OfficerKarin L. Walker is Chief Accounting Officer at Prothena Corporation plc, bringing three decades of financial management experience across public and private companies in roles including Chief Financial Officer and Controller. She has also served on the boards of Cyclacel Pharmaceutical Inc. and LifeSci Acquisition Corp.
TN
Tara Nickerson, Ph.D.Executive
WM
Wagner M. Zago, Ph.D.Executive
CD
Carol D. KarpinChief Regulatory Officer2016–2025Carol D. Karp is an executive officer at Prothena with extensive regulatory experience across global pharmaceutical and biotechnology companies, including prior roles at CV Therapeutics and Janssen Alzheimer Immunotherapy where she led regulatory strategies and product development from preclinical through commercialization stages.
GG
Gene G. KinneyinPresident & Chief Executive Officer
MJ
Michael J. MalecekChief Legal Officer and Company Secretary
BS
Brandon S. SmithinChief Operating Officer
CJ
Chad J. SwansoninChief Development Officer
WM
Wagner M. ZagoinChief Scientific Officer
RT
Richard T. CollierNamed on SEC filing
Investors · 4
Reported raises · per SEC filings
Form D private placements$50M disclosed across 1 round · 2018
▶$50MraisedMar 2018 · 1 investors · BiotechnologyRule 506(b)
▶$50MraisedMar 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard T. CollierDirector
- Tran B. NguyenExecutive Officer
- Arthur W. HomanExecutive Officer
- Lars G. Eckman, M.D., Ph.D.Director
- Dennis J. SelkoeDirector
- Karin L. WalkerExecutive Officer
- Tara Nickerson, Ph.D.Executive Officer
- Wagner M. Zago, Ph.D.Executive Officer
- Christopher S. Henney, Ph.D., D.Sc.Director
- Carol D. KarpExecutive Officer
- Shane M. CookeDirector
- Anders O. Harfstrand, M.D., Ph.D.Director
- Gene G. Kinney, Ph.D.Executive Officer, Director
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Mar 2018
- Incorporated
- Corporation, Ireland
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$465.9Mvaluation at IPOOct 2013 · $22.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 2
by search overlap
Robinhood29 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha29 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Prothena for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Prothena do?
- Prothena is a clinical-stage biotechnology company developing investigational therapies for neurodegenerative and rare peripheral amyloid diseases by targeting misfolded proteins. The company leverages its scientific legacy from Athena Neurosciences and collaborates with academic and industry partners to advance its pipeline of novel therapeutic candidates.
- Who are Prothena's investors?
- Prothena's investors include Sofinnova Ventures, Invesco, RA Capital, Wellington Management.
- How much funding has Prothena raised?
- Prothena has disclosed $50M raised across 1 round.
- Where is Prothena headquartered?
- Prothena is headquartered in Dun Laoghaire, Co. Dublin, US.